Avrobio Pauses Dosing in Phase 1/2 Trial of Gene Therapy for Gaucher
Due to the current COVID-19 outbreak, Avrobio announced that it has paused dosing new patients in clinical trials of its gene therapy candidates, including a Phase 1/2 study testing AVR-RD-02 in people with Gaucher disease type 1. This trial’s first Gaucher patient is enrolled and…